MA51007A - Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux - Google Patents

Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux

Info

Publication number
MA51007A
MA51007A MA051007A MA51007A MA51007A MA 51007 A MA51007 A MA 51007A MA 051007 A MA051007 A MA 051007A MA 51007 A MA51007 A MA 51007A MA 51007 A MA51007 A MA 51007A
Authority
MA
Morocco
Prior art keywords
phosphoramidate
anticancer compounds
nucleosides used
diphosphate salts
diphosphate
Prior art date
Application number
MA051007A
Other languages
English (en)
French (fr)
Inventor
Hugh Griffith
Fabrizio Pertusati
Michaela Serpi
Magdalena Slusarczyk
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of MA51007A publication Critical patent/MA51007A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MA051007A 2017-12-05 2018-12-05 Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux MA51007A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720279.7A GB201720279D0 (en) 2017-12-05 2017-12-05 Anticancer compounds

Publications (1)

Publication Number Publication Date
MA51007A true MA51007A (fr) 2020-10-14

Family

ID=60950385

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051007A MA51007A (fr) 2017-12-05 2018-12-05 Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux
MA051006A MA51006A (fr) 2017-12-05 2018-12-05 Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA051006A MA51006A (fr) 2017-12-05 2018-12-05 Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux

Country Status (22)

Country Link
US (2) US11560400B2 (enExample)
EP (2) EP3720864B1 (enExample)
JP (1) JP7268819B2 (enExample)
KR (1) KR20200092980A (enExample)
CN (1) CN111527098A (enExample)
AU (1) AU2018379713A1 (enExample)
BR (1) BR112020011221A2 (enExample)
CA (1) CA3082269A1 (enExample)
CL (1) CL2020001479A1 (enExample)
DK (1) DK3720864T3 (enExample)
EA (1) EA202091218A1 (enExample)
ES (1) ES2910165T3 (enExample)
GB (1) GB201720279D0 (enExample)
HR (1) HRP20220451T1 (enExample)
IL (1) IL274808B2 (enExample)
MA (2) MA51007A (enExample)
MX (1) MX2020005850A (enExample)
PH (1) PH12020550728A1 (enExample)
PL (1) PL3720864T3 (enExample)
PT (1) PT3720864T (enExample)
SG (1) SG11202004342TA (enExample)
WO (1) WO2019110991A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191461T1 (hr) 2014-11-28 2019-11-15 NuCana plc Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
CN116768949B (zh) * 2022-07-12 2026-03-03 南京工业大学 一种基于3’-脱氧腺苷经化学修饰改性的具有抗癌效应的化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2010135520A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
WO2014124430A1 (en) * 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
TW201542581A (zh) 2013-09-11 2015-11-16 艾默理大學 核苷酸與核苷治療組成物及其相關用途
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
HRP20191461T1 (hr) 2014-11-28 2019-11-15 NuCana plc Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
WO2016099982A2 (en) * 2014-12-15 2016-06-23 Emory University Phosphoramidates for the treatment of hepatitis b virus
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017106710A1 (en) 2015-12-17 2017-06-22 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017155923A1 (en) 2016-03-07 2017-09-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds

Also Published As

Publication number Publication date
JP7268819B2 (ja) 2023-05-08
CL2020001479A1 (es) 2020-12-18
EP4043471A1 (en) 2022-08-17
AU2018379713A1 (en) 2020-07-23
DK3720864T3 (da) 2022-04-11
HRP20220451T1 (hr) 2022-05-27
PT3720864T (pt) 2022-04-06
KR20200092980A (ko) 2020-08-04
PH12020550728A1 (en) 2021-02-15
IL274808B2 (en) 2023-08-01
GB201720279D0 (en) 2018-01-17
US20210171566A1 (en) 2021-06-10
IL274808B1 (en) 2023-04-01
EP3720864B1 (en) 2022-01-05
CN111527098A (zh) 2020-08-11
IL274808A (en) 2020-07-30
US20230192750A1 (en) 2023-06-22
MA51006A (fr) 2020-10-14
EA202091218A1 (ru) 2020-09-14
BR112020011221A2 (pt) 2020-11-17
MX2020005850A (es) 2020-09-07
JP2021505578A (ja) 2021-02-18
EP3720864A1 (en) 2020-10-14
PL3720864T3 (pl) 2022-05-02
ES2910165T3 (es) 2022-05-11
WO2019110991A1 (en) 2019-06-13
SG11202004342TA (en) 2020-06-29
US11560400B2 (en) 2023-01-24
CA3082269A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
FR24C1009I2 (fr) Composés utilisés comme inhibiteurs de kinase
EP3356356A4 (en) COMPOUNDS AS TRPM8 MODULATORS
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
IL263121B (en) Phosphoramidate nucleoside derivatives as anticancer agents
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
CO2018013105A2 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
PL3161154T3 (pl) Zmodyfikowane polimerazy do ulepszonego włączania analogów nukleotydów
MA43512A (fr) Composés hétérocycliques utiles en tant que modulateurs du tnf alpha
MA46373A (fr) Composés utilisés comme modulateurs de ror gamma
EP3494121A4 (en) CONTINUOUS CONNECTIONS
EP3509588A4 (en) BICYCLIC COMPOUNDS TO BE USED AS GPR120 MODULATORS
MX385579B (es) Forma cristalina de gemcitabina.
MA51006A (fr) Sels de phosphoramidate diphosphate de nucléosides utilisés en tant que composés anticancéreux
EP3848365A4 (en) TRK INHIBITORS AS AN ANTI-CANCER AGENT
EP3334703A4 (en) SYNTHESIS OF ARYLIC COMPOUNDS
MA52557A (fr) Composés de 1h-indazole-3-carboxamide utilisés en tant qu'inhibiteurs de la glycogène synthase kinase 3 bêta
EP3481806C0 (en) 4-anilino-quinoline compounds as anti-cancer agents
EP3353147A4 (en) SYNTHESIS OF TERPHENYL COMPOUNDS
MA55512A (fr) Sel de phosphoramidates de triphosphate de nucléotides en tant que composés anticancéreux
EP3494105A4 (en) CONNECTIONS AS INHIBITORS OF SODIUM CHANNELS
BR112019002828A2 (pt) método de preparação de derivados de estireno substituído
MA45787A (fr) Composés de thiazolo-pyridine substitués en tant qu'inhibiteurs de malt1